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Abstract 
 
Background: Tobacco smoking is known to be the single largest cause of 
premature death worldwide. The aim of present study was to analyse the effect 
of smoking on general and cause-specific mortality in the Estonian population. 
Methods: The data from 51,756 adults in the Estonian Genome Center of the 
University of Tartu was used. Information on dates and causes of death was 
retrieved from the National Causes of Death Registry. Smoking status, general 
survival, general mortality and cause-specific mortality were analysed using 
Kaplan-Meier estimator and Cox proportional hazards models. 
Results: The study found that smoking reduces median survival in men by 11.4 
years and in women by 5.8 years. Tobacco smoking produces a very specific 
pattern in the cause of deaths, significantly increasing the risks for different 
cancers and cardiovascular diseases as causes of death for men and women. This 
study also identified that external causes, such as alcohol intoxication and 
intentional self-harm, are more prevalent causes of death among smokers than 
non-smokers. Additionally, smoking cessation was found to reverse the 
increased risks for premature mortality. 
Conclusions: Tobacco smoking remains the major cause for losses of life 
inducing cancers and cardiovascular diseases. In addition to the common 
diseases, external causes also reduce substantially the years of life. External 
causes of death indicate that smoking has a long-term influence on the behaviour 
of smokers, provoking self-destructive behaviour. Our study supports the idea, 
that tobacco smoking generates complex harm to our health increasing mortality 
from both somatic and mental disorders. 
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Background 
 
Tobacco smoking is a single major cause of premature death worldwide [1, 2]. 
Despite substantial reduction in the use of tobacco, smoking still causes more 
deaths globally than diseases like tuberculosis, HIV and malaria combined, 
making it the largest preventable health risk factor [3, 4]. The use of tobacco is 
legally allowed and therefore the prevalence of smoking behaviour is still very 
high. While in the developed countries tobacco use is reduced and restricted, in 
developing countries the tobacco epidemic is still in the growing phase [1, 5]. It 
has been estimated that tobacco smoking causes globally 6 million deaths in a 
year [6]. 80% of these deaths are premature and affect lower income individuals 
[5]. This all makes tobacco smoking the largest single avoidable cause for 
mortality. Reducing the prevalence of smoking increases the health of the 
general population by avoiding premature disability and death. Smoking 
cessation and support to stop smoking are the easiest tools to improve the 
quality of life in population [7, 8]. 
 
While it is clear that smoking increases mortality, the association between 
smoking and mortality is different across specific causes of death. Cancers, 
chronic obstructive diseases of respiratory system and cardiovascular diseases 
are the most commonly referred smoking-induced causes of death. 
 
The association between smoking and lung cancer has been described already in 
1950 and following years [9-12]. Later studies found clear association with other 
cancers as well [13]. Tobacco smoking is known to cause cancers of upper 
gastrointestinal tract, pancreas, prostate [14]. While the association is conclusive 
for lung and upper respiratory tract cancers, the connection between smoking 
and other cancers does not have conclusive evidence. 
 
Tobacco smoking is reported to cause 90% of all chronic obstructive pulmonary 
disease (COPD) mortality and smoking cessation is the best measure to avoid 
this outcome [15]. The relative risk for smokers to die from COPD is 25.6 in men 
and 22.3 in women, compared to non-smokers [16]. Therefore, one of the most 
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common health problems in smokers is COPD [16, 17]. The development of 
COPD is dependent on the chronic persistent inflammation in the lung tissue that 
induces tissue-remodelling [18]. COPD is the most common and the most 
prevalent disease in smokers and smokers have very highly increased risk for 
COPD. 
 
Cardiovascular diseases have been found to be the third major cause of death 
caused by smoking [16, 19]. The main causes for death are ischaemic heart 
disease, cerebrovascular disease and other heart diseases [16]. Interestingly the 
risks caused by smoking of death due coronary heart disease are remarkably 
different between men and women [20]. Women who smoke have four times 
increased risk of death from ischaemic heart disease, while male smokers only 
have twofold increased risk [20]. For cerebrovascular diseases, this sex 
difference in risk has not been found [21]. This influence of sex on the risk of 
ischaemic heart disease is striking and its mechanism could be biological or 
behavioural. 
 
Increased prevalence of chronic diseases suggests increased inflammatory 
activity in smokers. Indeed, several studies indicate chronic inflammation in the 
smokers and different immunomodulating toxins in the smoke probably cause 
increased immune reactivity [22, 23]. A recent study analysed RNA expression 
profiles in the blood of smokers and non-smokers and identified a highly 
significant increase in the expression of GPR15 gene [24]. GPR15 is an orphan 
receptor that is responsible for the homing of tissue-specific immune cells [25]. 
 
Several previous studies have shown that the association between smoking with 
different causes of deaths is variable [26]. There are some large-scale population 
studies where causes of death and association with smoking have been 
addressed [7, 13, 16]. However, more detailed differential risk analyses for 
smoking and causes of death are not that common [27]. The goal of present 
study was to analyse the smoking-caused mortality in the Estonian Genome 
Center cohort and to describe the differential sensitivity for the different specific 
causes of death.  
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Methods 
The aim, design and setting of the study 
The aim of the study was to analyse smoking-induced mortality profile in Estonia 
using data at the Estonian Genome Center. Estonian Genome Center at the 
University of Tartu is a population-based biobank that recruited a cohort of 
51,756 participants, including adults from all counties in Estonia, accounting for 
approximately 5% of the Estonian adult population during the recruitment 
period. Recruitment was performed during the period from 2002–2012 [28]. At 
baseline, an extensive phenotype questionnaire was conducted together with a 
measurement panel. Follow-up data is available from linkage with national 
health-related registries and the Estonian Health Insurance database. Mortality 
information was retrieved from the Estonian Causes of Death Registry and last 
retrieval was performed in September 2015. 
The Ethics Review Committee on Human Research of the University of Tartu 
approved the protocols and informed-consent forms used in this study. All of the 
participants signed a written informed-consent form. 
 
Smoking data 
Smoking data were collected during the recruitment of donors to the Estonian 
Genome Center. The following questions were asked: 
1) “If you have ever smoked regularly, when did you start?” 
2) “How many of the tobacco products have you used during the last 12 
months?” 
3) “For how many years have you used tobacco products with this amount?” 
4) “What is the amount of tobacco products you used most commonly?” 
5) “For how many years you have used tobacco products as described?” 
 
Smoking behaviour was divided into three major categories: current smokers, 
former smokers and never smoked. Former smokers were individuals who had 
not smoked for at least one year prior to recruitment. 
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Statistical analysis 
All statistical analyses were stratified by sex, as previous analysis indicated 
significant differences in the smoking patterns between males and females. 
Statistical analysis was performed in R studio and packages "survival", 
"epitools", "Publish", "dplyr" were used. Survival data were modelled by using 
Cox model [29]. Survival was calculated from the date when subjects joined the 
Estonian Genome Centre cohort (2002-2012) and censored at date of death, 
retrieved from the National Death Registry, or September 2015, whichever came 
first. 
 
The data on smoking status, smoking intensity and smoking pattern was 
categorized (current, former and never smokers; smoking up to 10, 10–20 or 
more than 20 cigarettes per day; up to 20 years or more than 20 years of 
smoking history) and tabulated by four age groups (18–25, 26–45, 46–65 and 
more than 65 years). 
 
Mortality data was tabulated according to the cause of death, smoking status and 
sex of all participants. For survival analysis, the Kaplan-Meier estimator was 
used to plot survival curves. Starting time-point was the date when subjects 
joined the Estonian Genome Centre cohort and the end-point was the date of 
data retrieval from the National Death Registry. Cox proportional hazards 
regression analysis was used to calculate hazard ratio for all-cause mortality and 
cause-specific mortality, comparing current and former smokers with never-
smokers, using age as a time scale (to account for left-truncation in the data). Cox 
regression was also used to estimate the effects of smoking intensity (cigarettes 
per day) and length of smoking history on overall survival. Using the Kaplan-
Meier method for left-truncated data, the median survival time for current, 
former and never smokers in the cohort also was estimated with a 95% 
confidence interval. 
For cause-specific mortality, the causes of death according to the 10th Revision 
of International Statistical Classification of Diseases and Related Health 
Problems (ICD-10) were analysed separately in men and women. 
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Results 
General smoking characteristics in the cohort 
The Estonian Genome Center includes 51,756 participants: 17,777 men and 
33,979 women (Table 1), aged 18 and over at recruitment. The recruitment 
period was between 2002–2012. 
 
Basic demographic information and smoking characteristics are given in the 
Tables 2 and 3. Of all 17,777 men (Table 2), 39.4% were never-smokers, 20.8% 
former and 39.8% current smokers. Of all 33,979 women (Table 3), 67.3% were 
never-smokers, 10.0% former and 22.7% current smokers. This indicates clearly 
higher prevalence of smoking in Estonian men than women. The proportion of 
smokers in the cohort is similar to that of the general Estonian population[1]. 
According to the recent WHO data, the smoking prevalence in Estonian men is 
41.2% and in women 24.9%[1]. 
 
The average age to start smoking in men was 18 (SD 4.2) years and in women 21 
(SD 6.3) years. Analysis of the different age groups indicated that nowadays 
people start smoking at a younger age than in the past. Men in the age group 65+ 
had started smoking at age 20 and women at age 27 in the average. On the other 
hand, average age of starting to smoke in the youngest age group (18–25) was 16 
for both, men and women. 
 
The cohort was divided into two groups according to the duration of smoking – 
up to 20 years and over 20 years of smoking. In the study cohort, most of the 
smokers were smoking for less than 20 years. This trend also was valid in all 
subgroups of the cohort. 
 
The number of cigarettes per day differed significantly between male and female 
smokers. On average, men smoked 15 (SD 9) and women smoked 9 (SD 7) 
cigarettes per day. The average number of cigarettes per day was similar in 
current and former smokers. 
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All-cause mortality 
By September 2015, 3,364 (1,649 men and 1,715 women) people the cohort had 
died. The average age at death was 69 (SD 14) and 74 (SD 14) years for men and 
women, respectively. A general description of the more frequent causes of death 
and their association with smoking is given in the Table 4. 
 
The Kaplan-Meier curves for overall survival were significantly different in 
current, former and never smokers, in both men and women (Figure 1). The test 
for survival curve differences in men between three different smoking categories 
(“Never”, “Former”, “Current”) was highly significant (p=1.8*10-40). In case of 
women, the difference was also highly significant (p=1.3*10-14) for three-group 
comparison. The never smoked group had the longest survival and current 
smokers had the shortest survival. Survival of former smokers was in-between 
the never and current smokers indicating beneficial effect of quitting. 
 
Age-adjusted Cox regression of all-cause mortality in both sexes indicated 
significantly increased hazard ratio (HR) and 95% confidence interval (CI), for 
current 3.1 (CI 2.8–3.4) and former 1.6 (CI 1.5–1.8) smokers, compared to never 
smokers. When different sexes were analysed separately, almost similar results 
were seen. In male current smokers HR was 2.5 (CI 2.2–2.8) and in former 
smokers 1.3 (CI 1.2–1.5) for all-cause mortality. Currently smoking women had 
HR 2.6 (CI 2.2–3.0) and former smokers had 1.3 (CI 1.1–1.5) for all-cause 
mortality. Taken together, smoking status was significantly associated with 
increased all-cause mortality and this association was similar for men and 
women. 
 
Median age at death and loss of life years 
Smoking significantly reduced median age of death. In the entire study group, 
median age of death in never smokers was 85.7 (CI 85.4–86.2), in former 
smokers 80.6 (CI 79.6–81.6) and in current smokers 74.7 (CI 73.5–75.7) years. 
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The median age of death for men who never smoked was 82.6 (CI 81.4–83.6), for 
former smokers 78.4 (CI 77.1–79.4) and for current smokers 71.2 (CI 70.2–72.3) 
years. Median age of death for women who never smoked was 86.4 (CI 86.1–
86.8), for former smokers 85.8 (CI 83.4–88.1) and for current smokers 80.6 (CI 
77.9–81.8) years. 
 
Therefore, we estimate that the median loss of life years in smoking men is 11.4 
years and in women 5.8 years at lost. In the case of men, former smokers lived 
significantly longer than current smokers, but significantly less than never 
smokers. In the case of women, the difference in age of death of former and 
never smokers were very small. 
 
Effect of smoking duration and smoking intensity on all-cause mortality 
The increased risk for all-cause mortality was also significantly associated with 
smoking duration. Men who smoked more than 20 years had HR 2.1 (CI 1.9–2.3) 
and men who smoked less than 20 years had HR 2.3 (CI 2.1–2.5). Women with 
smoking duration more than 20 years had HR 2.7 (CI 2.4–3.1) and with less than 
20 years had HR 1.4 (CI 1.3–1.6). However, the number of cigarettes per day had 
a less severe influence on the all-cause mortality than smoking duration. 
 
Cause-specific mortality 
The subsequent analysis involved specific causes for mortality. The study cohort 
altogether had 272 unique ICD-10 main categories as cause of death. The most 
frequent causes of death (more than 100 cases) were chronic ischaemic heart 
disease (I25), hypertensive heart disease (I11), malignant neoplasm of bronchus 
and lung (C34) and cerebral infarction (I63) across the entire cohort (Table 4). 
Men and women also were analysed separately and for specific causes of death 
age-adjusted hazard ratio was calculated with non-smokers as reference. 
Statistically significant findings are shown in Tables 5 and 6. 
 
The most significant specific causes for mortality in currently smoking men were 
malignant neoplasm of bronchus and lung (C34, HR 32.9), heart failure (I50, HR 
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24.4), chronic obstructive pulmonary disease (J44, HR 23.1) and subsequent 
myocardial infarction (I22, HR 9.4) (Table 5, Figure 2). Current smokers also had 
a significantly increased hazard ratio to die from malignant neoplasms at 
unspecified sites (C80, HR 7.8). Interestingly, current smokers also had a 
significantly elevated hazard ratio for accidental poisoning by an exposure to 
alcohol (X45, HR 3.6), for cerebral infarction (I63, HR 3.3), for hypertensive heart 
disease (I11, HR 2.1) and chronic ischaemic disease (I25, HR 1.9) as causes of 
death. 
 
Compared to current smokers, former male smokers (Table 5) had significantly 
lower hazard ratio values for most of the causes of death. This finding illustrates 
a clear health benefit of quitting smoking as the general risk for death reduced 
from 2.5 to 1.3 and the number of specific causes for death decreased. In men 
who stopped smoking, only four causes of death remained statistically significant 
compared to those who have never smoked. These causes of death were chronic 
obstructive pulmonary disease (J44, HR 9.7), malignant neoplasm of bronchus 
and lung (C34, HR 9.2), subsequent myocardial infraction (I22, HR 5.4) and 
cerebral infarction (I63, HR 2.7). 
 
In the case of currently smoking women (Table 6, Figure 3) the highest hazard 
ratio as a cause of death were for chronic obstructive pulmonary disease (J44, 
HR 19.3), for alcoholic liver disease (K70, HR 13.9), for heart failure (I50, HR 
10.3) and for atherosclerosis (I70, HR 10.2). Current smokers also had increased 
hazard ratio for ill-defined and unspecified causes of mortality (R99, HR 8.5), for 
malignant neoplasm of bronchus and lung (C34, HR 6.7), for bacterial pneumonia 
(J15, HR 6.4), for acute myocardial infarction (I21, HR 4.7) and intentional self-
harm by hanging, strangulation and suffocation (X70, HR 4.6) as a cause of death. 
In currently smoking women, the hazard ratio for accidental poisoning by an 
exposure to alcohol (X45) was elevated, but this increase did not reach statistical 
significance. 
 
Smoking cessation significantly reduced the risks for specific causes of death and 
most of the hazard ratios were not different compared to the never smoked 
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group (Table 6). In former smokers only malignant neoplasm of the bronchus 
and lung (C34, HR 3.0) and malignant neoplasm of the ovaries (C56, HR 2.4) 
remained significant specific causes of death. 
 
Taken together, current smokers have significantly increased mortality and a 
specific pattern of cause of death. Respiratory and cardiovascular diseases were 
the most significant causes of death. This indicates, that smoking does the most 
harm to the lungs and cardiovascular system. The former smokers group had 
significantly less mortality than current smokers and therefore, smoking 
cessation significantly reduces the hazard ratio for cause-specific mortality. 
Former smokers still have significantly increased hazard to die from the lung 
diseases. 
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Discussion 
 
Based on the epidemiological analysis of tobacco smoking in the cohort of the 
Estonian Genome Center, this study concluded that Estonia still belongs to the 
group of countries with high number of smokers. On average, there are two 
times more smokers in Estonia than in Western-European countries. The high 
number of smokers also is characteristic for other Eastern-European countries. 
This statement is particularly true in men. In Estonia and other Eastern-
European countries around 40% of men are smokers, whereas in Western-
European countries only 10–20% of men are smokers. In the case of female 
smokers, Estonia is similar to Western-European countries, where 20% of 
women smoke [1]. This fits the typical epidemiologic pattern seen in Europe and 
developed countries. Differences between different countries are smaller in case 
of women and are prominent in the case of men. These differences also explain 
the significantly worse health of men in Eastern-European countries. Men smoke 
too much and they pay for that with their health and quality of life as seen by the 
reduced life span. 
 
The smoking prevalence in the Estonian Genome Center cohort is similar to the 
prevalence described in other study based on general population in three Baltic 
states [30]. In addition, the age-group prevalence of the Estonian Genome Center 
cohort is similar to the general Estonian population [28]. Therefore, our results 
are generalizable for the entire Estonian population. 
 
While the proportion of smokers in Estonia has been stable for 20 years, the age 
at which individuals start smoking tobacco has decreased remarkably. At 
present, people start to smoke at the median age of 16 and this is similar for men 
and women. This trend is worrisome and has an important impact on the health 
of the Estonian population. 
 
The age-group analysis indicated that men start to quit smoking at the age 46–
65, women start quitting 26–45. This indicates that women smoke for a shorter 
period of their life. Taken together, men start smoking earlier, they smoke more 
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cigarettes per day (mostly 20 cigarettes per day) and they quit smoking later. At 
the same time, women smoke less (mostly 10 cigarettes per day) they start 
smoking later and give up smoking earlier. This difference could also be 
detectable as the difference in survival and causes of death. Therefore smoking 
has a significantly larger impact on men’s health than in women. 
 
There present study analysed the impact of tobacco smoking on the hazard of all-
cause and cause-specific mortality. Survival analysis clearly indicated shorter 
median survival in smokers compared to non-smokers. Survival analysis also 
indicated that smoking cessation is beneficial for the survival. This means that 
toxic effects of smoking are reversible. The positive effect of quitting on the 
survival has been described in many previous studies [16, 17, 19]. 
 
Interestingly, in women the general survival differences caused by tobacco 
smoking were less prominent. For example, men who smoked lived on average 
11.4 years less than non-smokers, bud women who smoked only lost 5.8 years 
on average. In some previous studies, similar sex-differences in smoking effects 
have been found [31]. This sex-difference may be explained by the lower 
smoking activity in women. In our sample women smoked 9 cigarettes per day 
while men smoked 15 cigarettes per day on average. Women also start smoking 
later and quit earlier that makes their smoking duration shorter and this 
explains the reduced number of cigarettes smoked by women. Previous studies 
support this idea. If women smoke more they have mortality and morbidity 
profile similar to men and the sex differences disappear [32, 33]. 
 
The loss of years found from the survival analysis in the present study was 
similar to the findings from previous studies where loss of at least 10 years was 
found [17]. This indicates that the study design used and the results are 
comparable with other studies. For example, the study of Jha et al. analysed 
survival from the age 25 [17]. The present study included people from the age 18 
and mortality data were retrieved from the National Death Registry. This 
approach has been used for many previous studies. 
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The impact of smoking duration on general mortality gave somewhat 
controversial results as in men we found increased mortality in both groups 
compared to non-smokers. In case of men, the difference in general mortality 
between smoking more than 20 years and less than 20 years was very small (HR 
2.1 versus 2.3) and statistically not significant. In case of women, the difference 
related to smoking duration was significant. Women smoking more than 20 
years had HR 2.7 (CI 2.4–3.1) and women smoking less than 20 years have HR 
1.4 (CI 1.3-1.6). This finding is similar to the previously published findings [34]. 
Similarly, we found that number of cigarettes per day does not have impact on 
the all-cause mortality. 
 
The cause-specific analysis of death should describe the most common reasons 
why smokers lose years of their life. The comparison of causes of death induced 
by smoking in men and women identified very high similarities between both 
sexes in the pattern of cause of death. Namely, the most significantly smoking-
associated causes of death were diseases of the respiratory and cardiovascular 
systems both in men and women. This indicates that there is a common 
biological mechanism behind the smoking that increases morbidity and 
mortality. This mechanism is the same in men and women. One very good 
candidate for this common pathway is the GPR15 that was recently found to be 
upregulated in both male and female smokers [24]. 
 
In addition to the lung and heart diseases, the one of the largest hazard ratio was 
related to external causes of death. In men, this cause was death from accidental 
poisoning by an exposure to alcohol (X45). In women, these causes were 
alcoholic liver disease (K70) and intentional self-harm by hanging, strangulation, 
suffocation (X70). Alcoholic liver disease (K70) is closely related to a poisoning 
by an exposure to alcohol (X45) and should be taken as an external cause of 
disease. The significantly increased risks for external causes of death have been 
described in few previous studies and more detailed analysis is difficult to find 
[14]. The prevalence of alcohol poisoning and self-harm in former smokers as 
causes of death were the same in former smoker and non-smokers. This means 
that the increased incidence of suicide and alcohol intoxication in current 
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smokers could reflect particular biologically determined behavioural 
endophentoype and personality characteristics of current smokers. Smokers 
could be more impulsive or more prone to risk taking. One side of this behaviour 
is increased alcohol consumption, binge drinking and suicide. Not many studies 
indicate causes for this kind of association, but most probably there is common 
genetic variation between smokers and suicide victims. One recent study found 
an association between the polymorphic variable number tandem repeat (VNTR) 
in the SLC6A4 gene and increased risk for tobacco use disorder [35]. The 
association between polymorphisms in the BDNF gene and nicotine dependence 
also has been described [36]. Moreover, as tobacco smoking behaviour is often 
explained in conjunction with mood disorders, the link between suicide and 
smoking is not that surprising. At least one deletion in the GSTM1 and GSTT1 
genes has been described in anxious smokers while no association with mood 
disorders have been found [37]. 
 
One of the limitations of the study is the small number of several specific causes 
of death that could make our analysis imprecise. This small number is caused by 
the short time for observation. Currently it is impossible to get better 
estimations and this study can be a starting point for the repeated mortality 
analysis of the Estonian Genome Center cohort. Extended observation will 
eventually increase the number of specific causes and improve the precision of 
the analysis. In order to improve the regression analysis, we merged some cases 
(like J44, J45 and J47) that increased the power to estimate proportional hazard 
for smokers and ex-smokers. This helped to get more reliable HR estimations.  
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Conclusions 
In conclusion, the prevalence of tobacco smoking is still high in Estonia and men 
smoke at least two times more than women. This high prevalence is reflected in 
substantial loss of years of life and shorter survival of men. Smoking cessation 
can reverse the increased mortality, but the time needed for this reversal is not 
known. The two main types of cause of death in smokers were diseases of lung 
and cardiovascular system. The third group of cause of death is self-destructive 
behaviour. This finding suggests a common biological substrate in the brain of 
nicotine addicts and risk-taking behaviour. Better knowledge about the link 
between psychiatric illnesses and smoking could help to develop more effective 
interventions. Further studies are required to understand the genetic and 
biological background of this association. 
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Table 1 
Age distribution in the cohort of the Estonian Genome Center of the University of 
Tartu 2002–2012 
 
 Men Women Total 
Variable n % n % n % 
Age group       
18–25 3,896 7.5 5,302 10.3 9,198 17.8 
26–45 6,016 11.6 12,436 24.0 18,452 35.6 
46–65 5,292 10.2 11,257 21.8 16,549 32.0 
over 65 2,573 5.0 4,984 9.6 7,557 14.6 
Total 17,777 34.3 33,979 66.7 51,756 100.0 
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Table 2 
Smoking characteristics by age-group in the male cohort of the Estonian Genome 
Center of the University of Tartu 2002–2012 
 
 Age group 
 18–25 26–45 46–65 Over 65 Total 
Variable n % n % n % n % n % 
Smoking status           
Total 3,896 100.0 6,016 100.0 5,292 100.0 2,573 100.0 17,777 100.0 
Never smoker 1,854 47.6 2,281 37.9 1,783 33.7 1,093 42.5 7,011 39.4 
Former smoker 218 5.6 1,013 16.8 1,409 26.6 1,058 41.1 3,698 20.8 
Current smoker 1,824 46.8 2,722 45.3 2,100 39.7 422 16.4 7,068 39.8 
Age at start (SD) 16 (2.4) 18 (3.5) 19 (4.5) 20 (5.4) 18 (4.2) 
 Current smokers 
Years smoked (SD) 5 (2.8) 17 (6.5) 35 (7.1) 51 (8.0) 108 (14.7) 
Up to 20 years 1,773 100.0 1,772 66.8 52 2.5 4 0.9 3,601 52.3 
Over 20 years 0 0.0 879 33.2 1,991 97.5 409 99.1 3,279 47.7 
Cigarettes per day           
Number of persons 1,807 100.0 2,698 100.0 2,084 100.0 419 100.0 7,008 100.0 
Up to 10  634 35.1 551 20.4 299 14.4 102 24.3 1,586 22.6 
10–20  1,101 60.9 1,898 70.4 1,555 74.6 295 70.4 4,849 69.2 
Over 20  72 4.0 249 9.2 230 11.0 22 5.3 572 8.2 
 Former smokers 
Years smoked (SD) 4 (2.6) 11 (6.5) 22 (11.3) 29 (15.2) 20 (13.7) 
Up to 20 years 192 100.0 893 91.2 645 47.1 340 33.0 2,070 58.0 
Over 20 years 0 0.0 86 8.8 724 52.9 691 67.0 1,501 42.0 
Cigarettes per day           
Number of persons 163 100.0 766 100.0 1,095 100.0 869 100.0 2,893 100.0 
Up to 10  87 53.4 184 24.0 161 14.7 126 14.5 558 19.3 
10–20  72 44.2 515 67.2 791 72.3 661 76.1 2,039 70.5 
Over 20  4 2.4 67 8.8 143 13.0 82 9.4 296 10.2 
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Table 3 
Smoking characteristics by age-group in the female cohort of the Estonian 
Genome Center of the University of Tartu 2002–2012 
 
 Age group 
 18–25 26–45 46–65 Over 65 Total 
Variable n % n % n % n % n % 
Smoking status           
Total 5,302 100.0 12,436 100.0 11,257 100.0 4,984 100.0 33,979 100.0 
Never smoker 3,390 63.9 7,587 61.0 7,471 66.4 4,407 88.4 22,855 67.3 
Former smoker 328 6.2 1,374 11.0 1,334 11.8 366 7.3 3,402 10.0 
Current smoker 1,584 29.9 3,475 28.0 2,452 21.8 211 4.3 7,722 22.7 
Age at start (SD) 16 (2.2) 20 (4.4) 23 (7.3) 27 (10.0) 21 (6.3) 
 Current smokers 
Years smoked (SD) 5 (2.7) 16 (6.2) 29 (8.3) 42 (11.0) 92 (11.7) 
Up to 20 years 1,540 100.0 2,556 76.4 314 13.1 10 4.8 4,420  
Over 20 years 0 0.0 790 23.6 2,076 86.9 197 95.2 3,063  
Cigarettes per day           
Number of persons 1,570 100.0 3,435 100.0 2,436 100.0 211 100.0 7,652 100.0 
Up to 10  968 61.7 1,510 44.0 1,020 41.9 104 49.3 3,602 47.0 
10–20  584 37.2 1,842 53.6 1,363 55.9 104 49.3 3,893 51.0 
Over 20  18 1.1 83 2.4 53 2.2 3 1.4 157 2.0 
 Former smokers 
Years smoked (SD) 3 (2.4) 9 (6.1) 18 (10.7) 24 (14.9) 14 (10.9) 
Up to 20 years 293 100.0 1,210 94.7 768 60.9 162 45.6 2,433 76.3 
Over 20 years 0 0.0 68 5.3 494 39.1 193 54.4 755 23.7 
Cigarettes per day           
Number of persons 259 100.0 1,051 100.0 1,049 100.0 300 100.0 2,659 100.0 
Up to 10  183 70.6 573 54.5 571 54.4 160 53.3 1,487 55.9 
10–20  75 29.0 470 44.7 458 43.7 136 45.3 1,139 42.9 
Over 20  1 0.4 8 0.8 20 1.9 4 1.4 33 1.2 
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Table 4 
Basic characteristics of smoking, number of all causes of death and the most 
common cause-specific deaths in the studied cohort 
 
 Variable Men Women 
 Smoking status Current Former Never Current Former Never 
  n n n n n n 
 Persons in cohort 7,068 3,698 7,011 7,722 3,402 22,855 
 All causes death in cohort 627 548 474 270 147 1,298 
C16 Malignant neoplasm of stomach 8 13 10 10 5 34 
C18 Malignant neoplasm of colon 3 10 9 4 1 25 
C25 Malignant neoplasm of pancreas 11 18 11 12 6 32 
C34 Malignant neoplasm of bronchus and 
lung 
73 42 5 15 6 19 
C50 Malignant neoplasm of breast – – – 12 8 35 
C56 Malignant neoplasm of ovary – – – 5 8 25 
C61 Malignant neoplasm of prostate 16 17 29 – – – 
C80 Malignant neoplasm without 
specification of site 
9 – 2 4 – 9 
I11 Hypertensive heart disease 41 41 39 20 22 190 
I13 Hypertensive heart and renal disease 8 10 13 5 4 28 
I21 Acute myocardial infarction 16 11 12 6 4 31 
I22 Subsequent myocardial infarction 12 9 2 2 2 11 
I25 Chronic ischaemic heart disease 80 113 100 21 21 243 
I35 Nonrheumatic aortic valve disorders 5 2 6 1 1 17 
I42 Cardiomyopathy 16 9 12 5 2 11 
I50 Heart failure 10 2 1 4 1 17 
I63 Cerebral infarction 16 30 13 9 9 79 
I70 Atherosclerosis 2 3 5 2 1 11 
J15 Bacterial pneumonia 1 4 3 3 2 7 
J44 Chronic obstructive pulmonary disease 17 18 2 7 1 10 
K70 Alcoholic liver disease 8 7 6 7 0 2 
R99 Ill-defined and unspecified causes of 
mortality 
6 3 4 5 0 2 
X45 Accidental poisoning by and exposure 
to alcohol 
14 1 3 2 0 1 
X70 Intentional self-harm by hanging, 
strangulation and suffocation 
13 3 8 5 1 5 
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Table 5 
Smoking related adjusted hazard ratio (HR) and 95% confidence intervals (CI 
95%) for the statistically significant cause-specific mortality in men. 
 
 Variable Current smokers Former smokers 
 ICD-10 code for cause of death HR CI 95% HR CI 95% 
C34 Malignant neoplasm of bronchus and lung 32.9 13.2–82.0 9.2 3.7–23.4 
C80 Malignant neoplasm without specification 
of site 
7.8 1.5–39.5 – – 
C16–C80 Malignant neoplasms 4.0 2.1–5.4 1.7 1.2–2.3 
I11 Hypertensive heart disease 2.1 1.3–3.3 1.2 0.8–1.8 
I22 Subsequent myocardial infarction 9.4 2.0–43.3 5.4 1.2–24.8 
I25 Chronic ischaemic heart disease 1.9 1.4–2.6 1.3 0.9–1.7 
I50 Heart failure 24.4 2.8–213.1 2.1 0.2–23.4 
I63 Cerebral infarction 3.3 1.5–7.0 2.7 1.4–5.3 
I00–I99 Diseases of the circulatory system 2.6 1.8–2.7 1.3 1.1–1.5 
J44 Chronic obstructive pulmonary disease 23.1 5.2–101.8 9.7 2.3–41.7 
J00–J99 Diseases of the respiratory system 7.8 3.2–18.7 4.2 1.8–9.7 
X45 Accidental poisoning by and exposure to 
alcohol 
3.6 1.1–12.7 0.5 0.05–5.1 
V01–Y98 External causes of morbidity and mortality 2.2 1.5–3.3 0.8 0.5–1.4 
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Table 6 
Smoking related adjusted hazard ratio (HR) and 95% confidence intervals (CI 
95%) for the statistically significant cause-specific mortality in women. 
 
 Variable Current smokers Former smokers 
 ICD-10 code for cause of death HR CI 95% HR CI 95% 
C25 Malignant neoplasm of pancreas 4.0 1.9–8.3 1.9 0.8–4.7 
C34 Malignant neoplasm of bronchus and lung 6.7 3.2–14.4 3.0 1.2–7.6 
C56 Malignant neoplasm of ovary 0.9 0.3–2.5 2.4 1.1–5.3 
C16–C80 Malignant neoplasms 2.7 1.9–3.7 1.8 1.2–2.6 
I11 Hypertensive heart disease 2.2 1.3–3.6 1.4 0.9–2.2 
I13 Hypertensive heart and renal disease 3.3 1.1–9.8 1.7 0.6–4.9 
I21 Acute myocardial infarction 4.7 1.9–12.2 1.6 0.6–4.6 
I25 Chronic ischaemic heart disease 2.1 1.3–3.3 1.1 0.7–1.7 
I50 Heart failure 10.3 2.9–35.8 0.9 0.1–6.6 
I63 Cerebral infarction 3.4 1.6–7.0 1.6 0.8–3.1 
I70 Atherosclerosis 10.2 1.8–57.4 1.2 0.2–9.6 
I00–I99 Diseases of the circulatory system 2.7 2.1–3.5 1.3 1.0–1.7 
J15 Bacterial pneumonia 6.4 1.3–32.2 3.2 0.7–15.8 
J44 Chronic obstructive pulmonary disease 19.3 7.1–52.6 1.3 0.2–10.2 
J00–J99 Diseases of the respiratory system 12.0 5.3–27.3 1.8 0.5–6.1 
K70 Alcoholic liver disease 13.9 2.6–75.8 – – 
R99 Ill-defined and unspecified causes 
of mortality 
8.5 1.6–45.6 – – 
X70 Intentional self-harm by hanging, 
strangulation and suffocation 
4.6 1.2–18.1 1.6 0.2–13.7 
V01–Y98 External causes of morbidity and mortality 7.6 3.9–14.7 2.6 1.0–6.5 
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Legends to Figures 
 
Figure 1 
Kaplan-Meier survival probabilities for current and former smokers and for men 
and women who have never smoked. Reduced survival of the smokers is evident. 
 
Figure 2 
Forest plot of the hazard ratio (HR) for specific causes of death illustrates the 
profile of the major causes of death in currently smoking men. Age-adjusted Cox 
regression modelling was applied. 
 
Figure 3 
Forest plot of the hazard ratio (HR) for specific causes of death illustrates the 
profile of the major causes of death in currently smoking women. Age-adjusted 
Cox regression modelling was applied. 
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